D. E. Shaw & Co., Inc. Madrigal Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 53,800 shares of MDGL stock, worth $18.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

53,800

Holding current value

$18.6 Million

% of portfolio

0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $988,689 - $1.49 Million	-5,114 Reduced 84.38%	947 $265,000
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $1.64 Million - $2.71 Million	-9,561 Reduced 61.2%	6,061 $1.62 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $1.17 Million - $2.3 Million	9,708 Added 164.15%	15,622 $3.61 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $46,148 - $71,346	316 Added 5.64%	5,914 $863,000
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $3.94 Million - $6.03 Million	-19,340 Reduced 77.55%	5,598 $1.29 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $29.7 Million - $39.5 Million	-128,500 Reduced 83.75%	24,938 $6.04 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $7.62 Million - $38.7 Million	130,458 Added 567.7%	153,438 $44.5 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $48,395 - $63,528	799 Added 3.6%	22,980 $1.49 Million
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $33,953 - $58,617	-585 Reduced 2.57%	22,181 $1.59 Million
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $543,586 - $990,982	-9,726 Reduced 29.93%	22,766 $2.23 Million
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $414,652 - $545,055	-5,732 Reduced 15.0%	32,492 $2.75 Million
Q3 2021 Nov 15, 2021	BUY	$78.35 - $105.02 $1.32 Million - $1.77 Million	16,812 Added 78.52%	38,224 $3.05 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $1.33 Million - $1.88 Million	13,694 Added 177.43%	21,412 $2.09 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $423,414 - $488,405	3,901 Added 102.2%	7,718 $903,000
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $104,446 - $126,881	949 Added 33.09%	3,817 $424,000
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $486,059 - $613,506	-5,759 Reduced 66.76%	2,868 $247,000
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $523,724 - $818,947	5,747 Added 199.55%	8,627 $904,000
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $173,846 - $241,651	1,680 Added 140.0%	2,880 $361,000
Q2 2018 Aug 14, 2018	SELL	$101.55 - $313.9 $4.21 Million - $13 Million	-41,411 Reduced 97.18%	1,200 $336,000
Q1 2018 May 15, 2018	BUY	$93.35 - $149.04 $1.64 Million - $2.63 Million	17,619 Added 70.5%	42,611 $4.98 Million
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $983,435 - $2.43 Million	24,992	24,992 $2.29 Million

Others Institutions Holding MDGL

# of Institutions

298

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.9B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account